FDA 483 - Novo Nordisk Pharmaceutical Industries LP - August 29, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Novo Nordisk Pharmaceutical Industries LP in Durham, NC, was cited for multiple deficiencies during an FDA inspection. Observations included inadequate environmental controls for API storage, a lack of a comprehensive stability testing program, and insufficient hold time studies. Additionally, the firm failed to follow written procedures for blending alarms, demonstrated inadequate quality control oversight, and had an insufficient shipping validation for its Semaglutide API.
ID · 69885d7f-9345-48e0-97ea-a22d06fb73a0